Self-Adjuvanting Synthetic Antitumor Vaccines from MUC1 Glycopeptides Conjugated to T-Cell Epitopes from Tetanus Toxoid

  With the development of immunology, immunotherapy has been considered an effective way to treat disease. And vaccine plays a major role in immunotherapy. Compared with the traditional vaccine, chemical synthetic vaccine has homogeneous component andconfirmable structure. And in general, it contains the required antigen structure and immunostimulatingauxiliary structure.

  Chemical synthetic vaccine is always conjugated to carrier protein.However, carrier protein has large molecular weight and strong immunogenicity which can suppress the immunogenicity of antigen.

  To solve the problem, Prof. Yan-Mei Li's group had developed effective T-cell epitopes from Tetanus Toxoid. The T-cell epitopes were conjugated to the MUC1 antitumor glycopeptide vaccines.These vaccines could produce high level of effective antibody, which could recognize and effectively kill the cancer cells. This work was accomplished in collaboration with Prof. Horst Kunz from the University of Mainz, Germany and published on the AngewandteChemie International Edition (Cai, H.; Chen,M. S.; Sun, Z. Y.; Zhao, Y. F.; Kunz, H.; Li, Y. M. Angew. Chem. Int. Ed. 2013, 52, 6106-6110).